Discontinuation and Reinitiation of Mineralocorticoid Receptor Antagonists in Patients with Heart Failure and Reduced Ejection Fraction
Among patients with HFrEF initiated on MRA, 71% remained on therapy at 1 year. Discontinuation occurred early and was more common in patients with advanced kidney disease, hyperkalaemia, lack of follow-up in specialty care, more severe heart failure, comorbidities, and markers of sociodemographic frailty. Among those who discontinued, almost half reinitiated treatment the year following discontinuation.
Authors
- Gianluigi Savarese (ORCID: https://orcid.org/0000-0001-7732-0887)
- Ulrika Ljung Faxén (ORCID: https://orcid.org/0000-0002-0223-1588)
- Lina Benson (ORCID: https://orcid.org/0000-0002-5393-0055)
- Juan Jesús Carrero (ORCID: https://orcid.org/0000-0003-4763-2024)
- L Landucci
- Ulf Dahlström (ORCID: https://orcid.org/0000-0001-6353-8041)
- Lars H. Lund
Institutions
- Linköping University (SE)
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1002/ejhf.3523
- Citations
- 7
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 2.50
Funders
- Stockholms Läns Landsting
- Vetenskapsrådet
- Stockholm läns landsting